Jagsonpal Pharmaceuticals reports strong half-year profit growth, EPS up 39%

Jagsonpal Pharmaceuticals Limited has reported its unaudited financial results for the quarter and half-year ended September 30, 2025. For the half-year, the company's total income from operations reached INR 1,559.29 million, a substantial increase from INR 1,392.29 million in the corresponding period of 2024. Profit before tax and exceptional items also saw significant growth, rising to INR 312.41 million from INR 257.64 million year-on-year.

Net profit after tax for the half-year increased by 39% to INR 233.69 million, compared to INR 167.88 million in the previous year. This translates to basic earnings per share (EPS) of INR 3.50 for the half-year ended September 30, 2025, up from INR 2.52 in the same period last year. For the quarter ended September 30, 2025, total income from operations was INR 774.92 million, with a net profit after tax of INR 125.74 million.

The company's paid-up equity share capital as of September 30, 2025, stood at INR 133.27 million. These results reflect a positive financial trajectory for Jagsonpal Pharmaceuticals as it continues to navigate the market.